United Kingdom It on Monday became the first country to approve Moderna’s bivalent vaccine developed to attack the original COVID-19 virus and the Omron version. regulatory agency for drugs and health products (MHRA).
With this decision, it is expected that the vaccine will be used as a booster next fall, although the number of doses available is unknown at the moment. Health officials had already indicated that they would be introduced from next September. booster shot People over the age of 50 and those who are in the highest risk groups.
The original vaccines used during the pandemic were developed to combat the original form of the virus, which emerged in wuhan late 2019, but the virus has since mutated as new variants have emerged that can evade the immune system, causing outbreaks in several countries.
This is an updated version of Modern Vaccine
With this bivalent vaccine, In adults an injection is expected to be needed only once a year. Known as mRNA-1273.214, this dose is an updated version of the modern vaccine that has been given as first, second and booster doses.
According to the MHRA, side effects from the vaccine are similar to Moderna’s original booster dose and are usually mild. MHRA Executive Director, June Rhine, The new booster is described as “a fast tool in our arsenal” to protect the UK from COVID-19.
Goal: To increase antibodies against Omicron
“I am pleased to announce the approval of the Modern Bivalent Booster Vaccine” providing a robust immune response against the ba.1 omicron variant as well as the original 2020 strain, Raine said. Moderna’s medical director, Paul Burtonhave pointed out that the new injection can increase a person’s antibodies to such high levels that it may only be needed annually.
Stephen BanselModerna’s CEO describes it as a “Next Generation Covid-19 Vaccine” Which will “play a key role in protecting people in the UK from COVID-19” during the winter. “We are delighted with the MHRA authorization of our next generation COVID-19 vaccine, Spikevax Bivalent Original/Omicron,” Bansal told the media.
“This represents the first authorization of an Omicron-containing bivalent vaccine, further highlighting the dedication and leadership of UK public health authorities in helping to end the COVID-19 pandemic.”